6 active not recruiting, 3 recruiting, 2 terminated, 1 completed. 7 Phase 2, 6 Phase 3, 3 Phase 1.
Follow Rituximab and Hyaluronidase Human: new trials by email Literature Review of Rituximab and Hyaluronidase Human trials Research Report on Rituximab and Hyaluronidase Human
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial Biospecimen Collection, Computed Tomography, Cyclophosphamide - Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 102 | 2026-08-04 | 2026-10-13 |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma Biospecimen Collection, Computed Tomography, Mosunetuzumab - Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | Recruiting | National Cancer Institute (NCI) | 600 | 2024-10-23 | 2026-10-23 |
| Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-01-23 | 2026-10-14 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-06-22 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-10-01 |
| Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma Acalabrutinib, Bortezomib, Cyclophosphamide - Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Academic and Community Cancer Research United | 41 | 2021-08-03 | 2026-08-25 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-01 |
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Venetoclax, Lenalidomide, Rituximab - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | Thomas Jefferson University | 4 | 2020-10-16 | 2026-10-02 |
| Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Rituximab and Hyaluronidase Human, Cyclophosphamide, Vincristine - Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 18 | 2019-10-24 | 2024-01-03 |
| Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab - Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV | Phase 2 | Completed | Emory University | 15 | 2019-06-05 | 2026-10-02 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 689 | 2017-11-27 | 2026-09-14 |
Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Burkitt Lymphoma (2) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Melanoma (1) · Multi-centric Castleman's Disease (1)
National Cancer Institute (NCI) (5) · Academic and Community Cancer Research United (2) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · SWOG Cancer Research Network (1) · Thomas Jefferson University (1) · University of Washington (1)
United States (11) · Canada (2) · Australia (1) · Puerto Rico (1) · Saudi Arabia (1) · Uganda (1)
Catherine S Diefenbach (1) · Elizabeth A Brem (1) · Kavita Dhodapkar, MD (1) · Kristie A Blum (1) · Lisa G Roth (1) · Manoj Menon, MD (1) · Mazyar Shadman (1) · Nilanjan Ghosh (1) · Raphael E Steiner (1) · Stephen D Smith (1) · Stephen D. Smith (1) · Timothy S Fenske (1) · Ubaldo R Martinez-Outschoorn, MD (1)
PMID 33288485, PMID 34686472, PMID 36485104, PMID 40184567, PMID 42305039, PMID 42640721
U10CA180888 (3), P30CA015083 (2), U10CA180820 (1), U10CA180821 (1), U10CA180886 (1), UM1CA186691 (1)